Evaluation of Antithrombin Deficiency in Patients of Intensive Care Unit Placed on Extracorporeal Membrane Oxygenation
NCT04133844 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2021-06-04
Summary
Prospective, monocentric, non-interventional study in patients placed on extracorporeal membrane oxygenation (ECMO)
Conditions
- Severe Cardiac Insufficiency
Interventions
- BIOLOGICAL
-
Blood sample
Blood sample collection from a peripheral catheter at ECMO initiation (H0), then 2h, 6h, 12h, 24h and daily from day 2 to day 7 or at ECMO discontinuation
Sponsors & Collaborators
-
Rennes University Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-05-05
- Primary Completion
- 2021-05-18
- Completion
- 2021-05-18
Countries
- France
Study Locations
More Related Trials
-
Evaluation of the Relevance of Antithrombin Prescriptions at Strasbourg University Hospitals
NCT07276074 ·Status: RECRUITING
-
Antithrombin Supplementation in ECMO
NCT03208270 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Clinical Cohort Study of Safety and Effectiveness of Venous Thromboembolism Prophylaxis in Critical Ill Patients
NCT02213978 ·Status: COMPLETED
-
Bleeding Events After Triple Antithrombotic Therapy Initiation.
NCT03203980 ·Status: UNKNOWN
-
Anti-Xa Level With Thromboprophylactic Dosage Nadroparin in Critically Ill COVID-19 and Non-COVID-19 Patients
NCT05926518 ·Status: COMPLETED
-
PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT Pilot)
NCT00182364 ·Status: COMPLETED ·Phase: PHASE3
-
Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics
NCT01210755 ·Status: COMPLETED ·Phase: PHASE4
-
Predictors of Hypofibrinogenemia in Severe Trauma
NCT03020849 ·Status: COMPLETED
-
Anti-Xa Levels in Critically Ill Patients Receiving Low-molecular-weight Heparin for Thromboprophylaxis in China
NCT03311984 ·Status: UNKNOWN
-
Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia
NCT03269019 ·Status: UNKNOWN
-
Evaluation of the Interference of Antithrombotic Agents With Laboratory Monitoring of Heparin Therapy
NCT02839434 ·Status: TERMINATED
-
Thromboprophylaxis for Patients in ICU With COVID-19
NCT04623177 ·Status: COMPLETED
-
Heparin-Induced Thrombocytopenia: Development and Validation of a Predictive Clinical
NCT00748839 ·Status: COMPLETED
-
Safety and Efficacy of Argatroban Applicated in Anticoagulation of V-V ECMO
NCT04925167 ·Status: COMPLETED ·Phase: NA
-
Monitor System for the Safety of Dabigatran Treatment
NCT02414035 ·Status: COMPLETED
-
Anti-factor Xa Based Venous Thromboembolism Prophylaxis
NCT05221879 ·Status: COMPLETED ·Phase: NA
-
Dalteparin's Influence on Renally Compromised: Anti-Ten-A Study (DIRECT)
NCT00138099 ·Status: COMPLETED
-
Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients
NCT04412304 ·Status: COMPLETED
-
Safety and Feasibility of Argatroban As Anticoagulant in Adults with ECMO
NCT05226442 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Evaluating Dose Regimen of Intravenous Unfractionated Heparin and Low Molecular Weight Heparin in Critical Ill Patients Versus Critical Ill COVID-19 Patients Using Anti-Xa Levels.
NCT05224388 ·Status: COMPLETED
-
Response of Continuous Recombinant Antithrombin Infusion in Postcardiotomy ECMO Patients
NCT03090893 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia
NCT05848713 ·Status: RECRUITING ·Phase: PHASE3
-
Assessment of Thrombotic Status in Patients With Acute Coronary Syndrome
NCT02562690 ·Status: UNKNOWN
-
Generation of Thrombin and Prediction of Deep Vein Thrombosis Post Prosthetic Orthopedic Surgery of the Lower Limbs
NCT03634124 ·Status: COMPLETED ·Phase: PHASE3
-
Anti Xa Monitoring Low Molecular Weight Heparin on Prevention of Venous Thromboembolism
NCT05382481 ·Status: UNKNOWN ·Phase: NA